REG - Ondine Biomedical - Exercise of Options

Ondine BiomedicalAnnouncement

14/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250314:nRSN6554Aa&default-theme=true

RNS Number : 6554A  Ondine Biomedical Inc.  14 March 2025

14 March 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Exercise of Options

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, announces that it has received a
notice of exercise from a third party of the Company in respect of options
to subscribe for 16,666 new ordinary shares of no par value each in the
capital of the Company ("Ordinary Shares") (the "Option Shares") at an
exercise price of 9 pence per Option Share.

Application has been made for the Option Shares, which will rank pari
passu with the Company's existing Ordinary Shares, to be admitted to trading
on AIM ("Admission"). It is expected that Admission will become effective and
that dealings in the Option Shares will commence on or around AIM at 8.00 a.m.
on 19 March 2025. Following Admission, the Company's total issued share
capital will consist of 442,054,809 Ordinary Shares. As the Company does not
hold any shares in Treasury, this figure may be used by shareholders in the
Company as the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to their
interest in, the share capital of the Company following Admission.

 

Enquiries, please contact:

 Ondine Biomedical Inc.                                      www.ondinebio.com (https://ondinebio.com/)
 Carolyn Cross, CEO
Via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Financial Adviser)        +44 (0)20 7409 3494

James Harris, Richard Johnson
 RBC Capital Markets (Broker)                                 +44 (0)20 7653 4000

Rupert Walford, Kathryn Deegan
 Vane Percy & Roberts (Media Contact)                        +44 (0)77 1000 5910
 Simon Vane Percy, Amanda Bernard

 

About Ondine Biomedical Inc.

 Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEDXGDXBBBDGUX